|
| Tuesday, September 29, 2015 |
|
|
U.S. FDA Grants Priority Review Status to sNDA for Anticancer Agent Halaven as Treatment for Soft Tissue Sarcoma |
| Eisai Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Eisai's in-house developed anticancer agent Halaven (eribulin mesylate) as a treatment for soft tissue sarcoma, and granted the sNDA Priority Review status. more info >> |
|
|
Eisai Receives Additional Approval in Japan for Vascular Embolization Device DC Bead as Treatment of Hypervascular Tumors and Arteriovenous Malformations |
| Eisai Co., Ltd. announced today that it has received additional approval for the vascular embolization device DC Bead to be used for the treatment of hypervascular tumors and arteriovenous malformations (AVM) in Japan. more info >> |
|
| Friday, September 25, 2015 |
|
|
Eisai to Sponsor Lectures at Japan Research Center of Fudan University in China |
| Eisai Co., Ltd announced today that its holding company in China, Eisai China Holdings Ltd., will sponsor lectures at the Japan Research Center of Fudan University, one of China's top academic institutes, in Shanghai. more info >> |
|
| Monday, September 14, 2015 |
|
|
Eisai to Present Latest Clinical Data on Lenvima (Lenvatinib) and Halaven (Eribulin) at European Cancer Congress |
Eisai Co., Ltd. announced today that a series of abstracts highlighting the latest clinical data on Lenvima and Halaven will be presented during the European Cancer Congress (ECC) 2015, taking place in Vienna, Austria, from September 25 to 29.
more info >> |
|
| Thursday, September 10, 2015 |
|
|
Drugs for Neglected Diseases initiative and Eisai to Test Drug Candidate for Eumycetoma Patients suffering from virtually no R&D for this neglected disease |
| The Drugs for Neglected Diseases initiative (DNDi) and the Japanese pharmaceutical company Eisai Co., Ltd. have signed an agreement to proceed with the clinical development of Eisai's anti-fungal drug fosravuconazole for the potential new treatment of eumycetoma, a fungal form of mycetoma, one of the world's most neglected diseases. more info >> |
|
| Friday, July 31, 2015 |
|
|
Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and Pegph20 in Advanced Breast Cancer |
Eisai Co., Ltd. and Halozyme Therapeutics, Inc. announced today that they have signed a clinical collaboration agreement to evaluate Eisai's
anticancer agent eribulin mesylate in combination with Halozyme's investigational new drug PEGPH20 in first line HER2-negative advanced breast cancer. more info >> |
|
|
Continuation of "Policy for Protection of The Company's Corporate Value and Common Interests of Shareholders (Shareholder Rights Plan)" |
| The Board of Directors of Eisai Co., Ltd. passed a resolution for the continuation of the "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders", which was proposed by the Independent Committee of Outside Directors at its meeting held today. more info >> |
|
| Wednesday, July 29, 2015 |
|
|
Eisai's In-House Developed Novel Anticancer Agent Lenvima Receives Breakthrough Therapy Designation From U.S. Fda for Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today its U.S. subsidiary Eisai Inc. has received a Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its in-house developed novel anticancer agent Lenvima for the potential indication of advanced and/or metastatic renal cell carcinoma. more info >> |
|
| Friday, June 26, 2015 |
|
|
Eisai to Launch New Fine Granule Formulation of Tachyarrhythmia Treatment Tambocor Suitable for Pediatric Patients in Japan |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it will launch Tambocor Fine Granules 10%, a new formulation of anti-arrhythmic agent Tambocor (flecainide acetate), on June 29 in Japan. more info >> |
|
| Monday, June 22, 2015 |
|
|
U.S. FDA Approves Eisai's Antiepileptic Agent Fycompa as Adjunctive Treatment For Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an indication expansion regarding the use of its in-house developed antiepileptic agent Fycompa (perampanel hydrate) as an adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older. more info >> |
|
|
|
